Related Experiment Video

Updated: Jun 23, 2025

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

10.1K

TIPRL, a Potential Double-edge Molecule to be Targeted and Re-targeted Toward Cancer

Jie Gao1, Tiantian You1, Jiao Liu1

  • 1Department of Pharmacy, Zibo Central Hospital, Zibo, 255036, China.

Cell Biochemistry and Biophysics
|June 18, 2024
PubMed

Insights

The mechanistic target of rapamycin (mTOR) pathway and its regulator TIPRL are crucial in cancer cell growth and survival. Understanding their roles in apoptosis and proliferation is key to developing new cancer therapies.

Area of Science:

  • Cellular Biology
  • Biochemistry
  • Oncology

Background:

  • Target of Rapamycin (TOR) proteins are conserved across species and belong to the PIK-related kinase family.
  • Serine/threonine protein phosphatases (PP2A, PP4, PP6) are involved in TOR signaling in mammalian cells.
  • TOR signaling pathway regulator-like (TIPRL) protein regulates PP2A activity and is implicated in various cellular processes.

Purpose of the Study:

  • To review the significance of the TOR pathway in cancer cell apoptosis and proliferation.
  • To focus on the specific roles of TOR signaling and TIPRL in cancer development.
  • To explore the clinical relevance of TIPRL in carcinomas like NSCLC and HCC.

Main Methods:

  • Literature review of existing studies on TOR signaling, TIPRL, and cancer.
  • Analysis of the regulatory mechanisms of TOR and TIPRL in cellular processes.
  • Examination of reported TIPRL expression levels in various cancer types.

Main Results:

  • TIPRL has been observed at increased levels in non-small-cell lung carcinoma (NSCLC) and hepatocellular carcinomas (HCC).
  • TIPRL's proposed functions include regulating mTOR signaling, inhibiting apoptosis and biogenesis, and facilitating PP2A recycling.
  • The TOR pathway plays a significant role in controlling cancer cell proliferation and survival.

Conclusions:

  • The TOR pathway and TIPRL are critical regulators of cancer cell apoptosis and proliferation.
  • Elevated TIPRL levels in certain carcinomas suggest its potential as a biomarker or therapeutic target.
  • Further research into TOR signaling and TIPRL is warranted for cancer treatment strategies.
Keywords:
CancerPP2ARapamycinTIPRLTOR signaling

More Related Videos

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

16.7K
Bacterial Delivery of RNAi Effectors: Transkingdom RNAi07:56

Bacterial Delivery of RNAi Effectors: Transkingdom RNAi

Published on: August 18, 2010

13.5K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
2.4K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
511
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.6K